Questcor Pharmaceuticals Inc., of Hayward, Calif., named Kenneth Greathouse vice president, sales and marketing.
Ribozyme Pharmaceuticals Inc., of Boulder, Colo., appointed to its board of directors Samuel Saks, group vice president of Alza Pharmaceuticals, and John Groom, president and chief operating officer of Elan Corp. plc.
Ricerca LLC, of Painesville, Ohio, promoted John Peterson to vice president, corporate development.
Roche Pharmaceuticals, of Palo Alto, Calif., named Geoff Lawton vice president of chemistry and preclinical sciences in the neurobiology unit.
Select Therapeutics Inc., of Cambridge, Mass., named Bonni Dutcher director, program management.
Senomyx Inc., of La Jolla, Calif., appointed Mark Zoller vice president of research. In addition, it named to its board of directors David Schnell, managing partner of Prospect Venture Partners, and Kevin Tang, managing director at Deutsche Banc Alex. Brown.
SignalGene Inc., of Montreal, named to its board of directors Michael Dennis, chairman, president and CEO of Oncolytics Biotech Inc.
StressGen Biotechnologies Corp., of Victoria, British Columbia, appointed to its board of directors Kenneth Galbraith, executive vice president and chief financial officer of QLT Inc.
SuperGen Inc., of San Ramon, Calif., named John "Tipp" Nelson director, marketing of hematological products.
Techniclone Corp., of Tustin, Calif., named John Bonfiglio president and CEO.
The Brookings Institution, of Washington, named to its board of trustees William Haseltine, chairman and CEO of Human Genome Sciences Inc.
Theragenics Corp. Inc., of Buford, Ga., named to its board of directors Earnest Deavenport, chairman and CEO of Eastman Chemical Co.
Transkaryotic Therapies Inc., of Cambridge, Mass., named Michael Astrue senior vice president, administration and general counsel.
V.I. Technologies Inc., of Watertown, Mass., hired Kathleen Beach as vice president of clinical research; Bernadette Alford senior vice president/development and regulatory affairs; and James Moose senior vice president and general manager of plasma operations.
Valentis Inc., of Burlingame, Calif., named to its board of directors Mark McDade, president and chief operating officer of Corixa Corp.
Variagenics Inc., of Cambridge, Mass., named to its board of directors Anthony Wild, former president of the pharmaceutical sector at Warner-Lambert Co., and William Scott, an adjunct professor at Rockefeller University.
ViroPharma Inc., of Exton, Pa., elected to its board of directors Michel de Rosen, chairman and CEO of MR Enterprises.
ZymoGenetics Inc., of Seattle, named to its board of directors George Rathmann, founder of Amgen Inc. and current president and CEO of Hyseq Inc., and Edward Penhoet, former president and CEO of Chiron Corp.